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The Role Of Neutrophils In Pancreatic Cancer 
 
Edson DeOliveira, M.S. 
University of Nebraska Medical Center, 2019 
 
Advisor: Leah Cook, PhD 
Pancreatic cancer is the fourth leading cause of cancer-related mortalities and the 
American Cancer Society estimates that 56,770 people will die of the disease in 2019. Known 
mutations include Kras oncogene, cyclin-dependent kinase inhibitor 2A (CDKN2A), TP53 and 
SMAD4. The current standard-of-care includes chemotherapies, but despite such approaches 
advanced staged patients have a relative 5-year survival rate of 8.5% overall. Immune cells such 
as neutrophils are believed to play a dual role in tumor eradication or tumor promotion. The aim 
of this study was to understand the effect of primary and metastatic pancreatic cancers on 
neutrophil NET formation and how NETs influence cancer cell survival. Results showed 
increases in neutrophil viability and NET formation in both nonmetastatic and metastatic 
condition medias. In patient samples, colocalization staining for myeloperoxidase (MPO) and 
citrullinated H3 (CitH3), differences in neutrophil infiltration and NET formation across tissue 
sample sites were observed but found to be not significant. However, in-vitro cocultures of 
neutrophil-cancer indicated that NET mediated reduction in cancer cell number was greater than 
40% in nonmetastatic cell lines when compared to metastatic, and this alleviated by addition of a 
NET inhibitor GSK484. In an orthotopic mouse model, injection of luciferase expressing primary 
tumor (MiaPaca-2) cells, anti-Ly6G antibody neutrophil depleted groups showed hindered 
increases in tumor size suggest neutrophils may have had protumor role. However, final tumor 
size increase in neutrophil depleted groups was significant when compared to control, suggesting 
that additional cell populations may have modulated a tumor supporting function in place of 
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Chapter 1: Introduction 
 
Pancreatic Cancer Clinical Implications 
The American Cancer Society estimates that 56,770 people (29,940 men and 26,830 
women) will be diagnosed with pancreatic cancer and 45,750 will succumb to the disease in 
2019. The causes of pancreatic cancer are still insufficiently known, although certain risk factors, 
common in other cancers but applicable to pancreatic care, including genetics, diabetes, diet, 
obesity, lack of exercise, and smoking, have been identified as predisposing individuals to higher 
rates of incidence (Ilic, 2016). Additionally, the risk of developing pancreatic cancer increases 
with age with over 80%  of pancreatic cancer cases developing between the ages of 60 and 80 
years (Yadav, 2013). With limited early detection methods, diagnosis often occurs at a late stage 
of the disease with fewer than 20% of patients being eligible for surgical resection (Martisian, 
2019).  
The current standard-of-care therapy includes chemotherapies, such as gemcitabine and 
folfirinox with or without radiation, with immunotherapies such as monoclonal antibodies (mAb) 
and antibody drug conjugates currently under development (Chiorean, 2015). Given its late 
diagnosis, individuals with advanced pancreatic cancer have a very poor prognosis, with a 
relative 5-year survival rate of 8.5% overall (Sohal, 2017). Current detection strategies for curable 
precursor lesions involve exploration of pancreatic cancer stromal markers. The benign tumor to 
malignant cancer transformation commonly seen in various cancers follows the sequence of 
initiation, clonal expansion, and metastasis to foreign microenvironments (Makohon-Moore, 
2016). This sequence of events has led to screening for silent pancreatic neoplasias in individuals 
with family histories of pancreatic cancer (Kong, 2012). Of importance were screenings for 
potential tumor promoting factors expressed by molecules within the stromal environment. 




in histological classification, could better validate early identification in pancreatic intrepithelial 
neoplasias (PanIN) to more severe pancreatic ductal adenocarcinoma (PDAC) progression 
models. Highlighted structural changes can be seen in various stages of pancreatic cancer with an 











Figure 1|Histological features of PanINs and PDAC. A. Normal histology with (D) indicating a duct; (I) indicating a 
pancreatic islet cell; (A) showing pancreatic acinar cells. Staging dependent on extent of atypical cytological structure. 
PanIN1 A,B, arrows illustrate elongation of ductal cells with minimal nuclear deformation highlighting precancerous 
condition. PanIN 2 arrows indicate loss of mucous epithelium, nuclear crowding, and mitotic figures. PanIN3 
corresponds to pseudopapillary formation and carcinoma, high nuclear pleomorphism, and intraluminal debris. Figure 
from (Makohon-Moore, 2016). 
 
Most pancreatic cancers occur sporadically, with several molecular profiling studies 
illustrating the mechanisms involved in the established PanIN-to-PDAC progression model 
(Makohon-Moore, 2016). Histological aspects of PanIN transformations and staging are classified 
into three grades: low grade lesions with minimal architectural dysplasia designated as PanIN-1A 
(flat) and PanIN-1B (papillary), intermediate grade PanIN 2 with nuclear crowding and moderate 
atypical cytological appearance, and high grade PanIN 3 with high nuclear pleomorphism and 
carcinoma formation (Distler, 2014). Genetic mutations correlated to each stage are as follows: 
low grade PanIN lesions having point mutations in the Kras oncogene and telomere shortening, 
intermediate grade having inactivating mutations of cyclin-dependent kinase inhibitor 2A 






TP53 and SMAD4 (Guo, 2016).  Early detection and treatment of these precursor lesions could 
probably save patients from advancing to invasive pancreatic cancer (Pittman, 2017). However, 
extensive evaluation into the molecular signaling of pancreatic cells undergoing cancerous 
transformation and progression is needed to further elucidate potential gene targets for therapeutic 
intervention.  
Stromal Environment 
Despite pancreatic cancer’s association with these specific mutations, therapeutic 
targeting of these mutations have proven to be clinically ineffective. Stromal cells can account for 
nearly 90% of pancreatic tumor volume and can contribute significantly to tumor progression. 
Although various signal transduction pathways and genetic mutations have been identified, there 
remains a need for development of early detection methods, as well as combining 
chemotherapeutic with immune targeted therapies towards the microenvironment to control 
disease progression and survival. Stromal cells of note consist of cancer-associated fibroblasts 
(CAFs), pancreatic stellate cells (PSCs), myeloid derived suppressor cells (MDSCs), as well as 
large populations of macrophages and neutrophils/polymorphonuclear leukocytes (PMNs) 
(Nielsen, 2016).   
PSCs are essential to extracellular matrix formation and maintenance under normal 
conditions. The balance of this profibrogenic capability is disrupted when PSCs are activated by 
cancer cells to become cancer-associated human PSCs (CA-hPSCs) that promote 
chemoresistance, local tumor progression, and metastasis (Philips, 2012). The cumulative effects 
of disease onset by compromised cells release increased levels of cytokines, reactive oxygen 
species (ROS), and growth factors which stimulate quiescent PSCs to increase expression of α-
smooth muscle actin (α-SMA) (Koikawa, 2018). The degree of PSC and graded fibrosis activity 
has been indicated as a stromal activity index, a ratio of α -SMA to the density of collagen 




prognostic tool was evaluated in a study with 233 post-surgical pancreatic cancer patients where 
high stromal activity index scores were positively correlated with low prognosis (Erkan, 2008). 
In-vivo xenograft models using nude mice evaluated the ability of CA-hPSCs to protect 
pancreatic cells in mice which received subcutaneous injections of solely human pancreatic cells 
or in combination with human PSCs (Mantoni, 2011). Results of this study showed tumor growth 
was more pronounced in those formed from both human PSCs with pancreatic cells in response to 
radiation therapy, versus those formed only from pancreatic cells alone (Mantoni, 2011). 
Collectively, the role of CA-hPSCs in pancreatic cancer chemoresistance and progression is 
paramount to cancer cell survival. Thus, reducing the activity of CA-hPSCs by better 




Figure 2| Immunohistochemical analysis comparing collagen deposition versus stellate cell activity around cancer 
structures. Immunohistochemistry performed using an anti-SMA antibody (brown) to detect activated PSCs and aniline 
(blue) to stain collagen fibers (B and D). (A and C) Density of activated PSCs increased around cancerous (unstained) 








Being the most abundant white blood cells (WBCs) to an immune response, neutrophils 
account for 50-70% of leukocyte populations. Under normal physiological conditions, neutrophils 
act as first responders to inflammation and infections that is resolved by macrophages.  
Granulopoiesis, the process of neutrophil development, occurs predominantly in the bone 
marrow. During granulopoiesis, long-term hematopoietic stem cells (LT-HSC) differentiate into 
short-term hematopoietic stem cells (ST-HSC) followed by multipotent progenitor (MPP) cells 
(Nicolas-Aliva, 2017). Neutrophil differentiation, under the influence of granulocyte-colony 
stimulating factor (G-CSF), then continues through the subsequent stages: lymphoid-primed 
multipotent progenitors (LMPPs) GMP, myeloblast, promyelocyte, myelocyte, metamyelocyte, 
band neutrophil, mature neutrophil, and finally segmented neutrophil as illustrated in (Fig. 3)
 
Figure 3 |Hematopoietic development of neutrophils. The development of neutrophils from long term hematopoietic 
stem cells (LT-HSC) to ST-HSC, MPP, LMPP, GMP, Myeloblast, promyelocyte, myelocyte, metamyelocyte, band cell 
and mature neutrophils. Cell surface molecule expression levels fluctuate dependent on stage of development. Ligands 
to CXCR4 retain neutrophils, while, CXCR2 recruit mature neutrophils out into circulation. Image by (Coffelt, 2016). 
 
Neutrophils contain an abundance of antimicrobial compounds stored within granules. 
Throughout their developmental stages, neutrophil granules begin to appear at distinct stages. 




granules appear between the myelocyte to metamyelocyte stage, tertiary (gelatinase) granules 
take on appearance during the band cell to segmented stages (Coffelt , 2016). As neutrophils 
mature, they down regulate expression of various receptors such as KIT and C-X-C chemokine 
receptor 4 (CXCR4), while upregulating others such as CD11b, Ly6G in mice, CXCR2 and Toll-
like receptor 4 (TLR4) (Coffelt, 2016). Mature neutrophils, primed for mobilization into 
circulation, express ligands for CXCR 2, which include CXCL2, CXCL5, and CXCL8. Of note,  
CXCL2, and CXCL5 are known to mobilize mature and hypersegmented neutrophils out of the 
bone marrow and egress into the bloodstream. Primarily, chemokines regulate the balance 
between neutrophil retention and release. Bone marrow stromal cells produce CXCL12 that binds 
CXCR 4, leading to neutrophil retention, while release is controlled mainly by CXCR2 signaling 
(Nywening, 2017). Circulating mature neutrophils have a short life span of several hours to one 
day before undergoing apoptosis either at distant tissue sites or after returning to the bone marrow 
(Borregaard, 2010).   
 
Neutrophil Immune Response In Disease 
Neutrophil mechanisms for neutralizing pathogens involve: 1) degranulation of 
bactericidal enzymes, including myeloperoxidase (MPO), neutrophil elastase (NE), and cathepsin 
G, 2) release of reactive oxygen species (ROS), also known as oxidative burst, and 3) release of 
web-like decondensed nuclear DNA called neutrophil extracellular traps (NETs),  a process 








Figure 4|Net Formation. Illustration of active neutrophil undergoing NETosis. Expelled decondensed DNA contains 
various proteases including neutrophil elastase (NE, myeloperoxidase (MPO), cathepsin G, and histones in response to 
microbial pathogens. Figure by (Miyata, 2012). 
 
NETs are a classical cytotoxic response characterized by chromatin decondensation 
(induced by peptidyl arginine deiminase 4 (PAD4) histone citrullination), dissolvement of the 
nuclear and granule membranes, and mixing of chromatin and granule enzymes that are secreted 
as a sticky meshwork for trapping and killing bacteria (Merza, 2015). NETosis is stimulated by 
phorbol-myristeacetate (PMA), lipopolysaccharide (LPS), interferon-gamma(IFN-γ), and 
microbial pathogens (Almyroudis, 2013). NETs contain an arsenal of granular proteases such as 
serine-proteinase neutrophil elastase (NE), matrix metalloproteinases MMP-8 and MMP-9, and 
myeloperoxidase. The NADPH oxidase enzyme in neutrophils is also associated with NET 
formation. Activation of neutrophils through the recognition of various pathogenic stimuli, 
activates the NADPH oxidase complex through protein kinase C (PKC)/Raf/MERK/ERK, as well 





Figure 5| Molecular pathways involved in NETosis. Microbial interaction with pathogen recognition receptors or 
phorbol-myristeacetate (PMA) induced elevation of intracellular calcium on neutrophils subsequently activates protein 
kinase C (PKC) and NAPDH oxidase. Reactive oxygen species (ROS) generated by NADPH oxidase leads to 
downstream signaling mediated by Akt, extracellular signal regulated kinase (ERK1/2) and p38 mitogen-activated 
protein kinase (MAPK). Chromatin decondensation requires relocation of myeloperoxidase (MPO) and neutrophil 
elastase (NE) into the nucleus and histone citrullination (citH3), mediated by peptidylarginine deiminase 4 (PAD4). 
Activated platelets in response to lipopolysaccharide (LPS) or agonists such as thrombin can stimulate neutrophils to 
produce NETs via soluble or cell-mediated interactions. Image from (Boysen, 2018). 
 
More recently, PADs have been implicated as critical mediators of NETosis and serve as 
a potential target for NET associated diseases. There are five peptidyl arginine deaminases (PAD) 
which consist of PADs 1,2,3,4, and 6. PADs 2 and 4 are the only two involved with 
hematopoietic cell lines, thus play an important role in signaling process of the immune system 
(Vossenaar, 2003). Although expressed by some cancers, PAD4 is primarily expressed by 
granulocytes and its activity is calcium dependent (Merza, 2015). Histone citrullination by PAD4 
aids in NET formation by promoting decondensation of the chromatin structure and ejection of 
DNA and is critical to neutrophil response to pathogenic infection (Rohrbach, 2012). This was 
shown using PAD4-/- mice (Hemmers, 2011) in which PAD4-/- neutrophils were unable to produce 
NETs due to reduced histone citrullination and, as a result, increased susceptibility to microbial 




The generation of NETs can produce varied effects. On the one hand, they may promote 
pathogen killing. However, the same pathways that control microbial infection can also cause 
injury through several mechanisms. NET products can damage epithelial and endothelial cells, 
which can exacerbate inflammation induced organ injury (Saffarzadeh, 2019). This highlights the 
importance of NETs in autoimmune and autoinflammatory pathologies, such as rheumatoid 
arthritis, systemic lupus erythematosus (SLE), vasculitis, lung injury, atherosclerosis, and 
thrombosis (Kruger, 2015). Several strategies have been proposed to interfere with NETs, 
particularly digestion of NET DNA with DNase1, targeting NET-associated proteins, and PAD 
inhibitors (Jones,2009). Due to their potential role in human disease, PAD inhibitors are of high 
interest. For example, the compound Cl-amidine, acts via irreversible inhibition by preferentially 
inactivating the calcium bound form of the enzyme (Biron, 2017). In a mouse model of SLE, 
systemic treatment with the PAD4 inhibitor, BB-Clamidine, was shown to protect mice from 
developing NET-mediated vascular damage, endothelial dysfunction and kidney injury (Knight, 
2013). Sepsis models demonstrated that PAD4 deficiency in PAD4-/- mice improved overall 
survival and showed decreases in organ dysfunction without exacerbating bacteremia (Biron, 
2018). Nonetheless, due to the physiological complexities of systemic PAD4 inhibition, 
developing a suitable targeted therapy for PAD4 remains to be seen. 
  
Tumor Associated Neutrophils 
In recent years, neutrophils have received more attention in the context of tumorigenesis 
driven by inflammation. Within this context is the concept that tumor associated neutrophils 
(TAN) are believed to have differential activation states which correspond to anti-tumor or pro-
tumor effects (Nicolas-Aliva, 2017). This is believed to be a result of overexpression of several 
cytokines. Of note, TGF-β has been highlighted as having protumor effects via its release and 
interaction within the microenvironment. Neutrophils acquire phenotypes which are protumor 




tumor (N1 TAN) that are induced by the presence of low TGF-β and high IFN-y (Felix, 2016). 
N2 TANs promote invasion, growth and metastasis through degradation of the extracellular 
matrix (ECM), angiogenesis, and immunosuppression, while N1 TANs abrogate tumor 
progression through tumor cell toxicity and enhancement of the antitumor immune memory 
response (Piccard, 2012). Concurrently, TGF-β has been shown to impact myeloid cell functions 
by polarizing macrophages to become protumor (M2) versus antitumor (M1) (Fridlender, 2009). 
An important distinction to note is that unlike M2 tumor-associated macrophages which 
characteristically express CD206, there are no clear cell surface markers distinctive to TANs 
which exhibit cell plasticity and tissue context dependent functions, (Meri, 2018).   
 
In proinflammatory diseases, certain proteases derived from neutrophil granular enzymes 
such as NE and MMPs, can modify the ECM, a phenotype shown to contribute to cancer 
progression by degradation of the basement membrane. (Swierczak, 2015). NE is stored in 
primary azurophilic granules with its antimicrobial action being counterbalanced primarily by α1-
antitrypsin and other natural inhibitors. An imbalance between NE and its inhibitors has been 
implicated in tumor development such as liver, lung cancers, and increased concentrations of NE 
in cancers has been correlated with poor survival (Sun, 2004).  Using a mouse model of lung 
adenocarcinoma of Kras activation, one study showed that NE expression increased lung tumor 
growth and decreased overall survival time in Kras/NE positive mice when compared to Kras/NE 
deficient mice (Houghton, 2010). This same study further indicated that NE has a direct effect on 
inducing tumor cell proliferation. NE effects on proliferation were dosage dependent in which 
higher concentrations induced cell death, and moderate concentrations resulted in cell 
proliferation (Houghton, 2010). Of note here is that NE concentration levels could relate to 
neutrophil activation states and the need for further study as to how these differential states are 





MMPs are the primary factors which function to degrade the ECM. Overexpression of 
MMP-2 and MMP-9 in pancreatic cancer was previously reported, and these gelatinases were 
also investigated as differential markers for chronic pancreatitis (CP) and PDAC (Wang, 2019). 
For instance, MMP-9 expression by TANs promotes angiogenesis and cleavage and activation of 
CXCL8 which is expressed by tumor cells (Nicolas-Aliva, 2017). Furthermore, MMP-9 cleaves 
the substrate endothelin ET-1(AA 1–38) into ET-1(AA 1–32) which activates neutrophils and 
promotes leukocyte-endothelial cell adhesion and subsequently, neutrophil trafficking into 
targeted areas of inflammation (Iyer, 2012).  Other studies have shown that neutrophil derived 
MMP-9 is a direct inducer of pancreatic tumor angiogenesis. Together, these observations suggest 
that PMN derived MMP-9 has a direct proangiogenic effect and is essential for tumor-associated 
blood vessel formation and tumor growth (Deryugina, 2015). 
 
Neutrophils in Pancreatic Cancer 
 During infections, chronic inflammation, and malignancies neutrophil are systematically 
expanded in the bone marrow, released into circulation and recruited to the site of disease or 
tumor in response to chemotactic factors such as granulocyte-macrophage CSF (GM-CSF), G-
CSF, or neutrophil- attracting CXC-chemokines (Gabrilovich, 2012). Once in circulation, cell 
adhesion molecules located on neutrophils surface (CD11b) as well as adhesion molecules on the 
surface of blood vessel endothelial cells (selectins, ICAM-1 and PECAM-1) are crucial in the 
rolling, adhesion, and transmigration of the neutrophils from the bloodstream into the tumor 
(Cerutti, 2017).  
 
Upon infiltration into the pathogenic site, neutrophils join a diverse desmoplastic cellular 
stroma of the microenvironment that consists of cells such as macrophages, anti-inflammatory 
myeloid-derived suppressor cells (MDSCs), as well as stellate cells, fibroblasts, and 
hematopoietic progenitor cells (Makohon-Moore, 2016). In an orchestrated fashion, these 




transformation, and progression (Kruger, 2015).  In addition, granulocytic MDSCs interfere with 
T-cell proliferation (Fig. 6).  
 
 
Figure 6| Potential role of monocyte and neutrophil associated myeloid suppressor cells (MDSCs) in the regulation of 
tumor development and progression.  Tumor development is associated with the expansion of cells with acquired 
immunosuppressive activity (MDSCs). These cells also promote tumor cell invasion and angiogenesis and neutralize 
tumor cell senescence. Image by (Marvel, 2015). 
 
A mechanism of MDSC immune suppression includes release of reactive oxygen species 
(ROS), arginase-1 (arg-1), and nitric oxide (NO) (Porembka, 2012). More recently, it has been 
shown that peroxynitrite (PNT), created as a byproduct of NO and superoxide interactions, could 
cause nitration of T cell receptor-CD8 complex which reduced its binding to the peptide MHC 
class I (pMHC) complex, and rendered T cells unresponsive to antigen-specific stimulation 
(Marvel, 2015).  These effects illustrate the promoting effects stromal cells have on tumor 
progression. In line with this, neutrophil recruitment and infiltration into cancer exacerbate 
disease progression.  
 
 As discussed previously, TANs play an important role in cancer development, 




strongly correlated with poorer prognosis (Reid, 2011).  High intratumoral CXCL5, a chemokine 
for neutrophils, have also been associated with poorer overall survival (Hu, 2018)). In a KPC 
mouse model, GR1+ myeloid cells, which includes neutrophils, were depleted using mAbs and 
showed increased infiltration of effector T cells and inhibited tumor growth (Stromnes, 2014). 
Therefore, targeting neutrophils may be therapeutic in PDAC. CXCR2 ligands are essential for 
neutrophil egression from the bone marrow and trafficking toward sites of inflammation and for 
the recruitment of TANs in various cancers (Fu, 2018). The importance of high infiltration of 
TAN has been used to assess patient prognosis in relation to neutrophil/lymphocyte ratios.  
 
As discussed previously, TGF-β is known to drive neutrophils toward a protumor (N2) 
phenotype. Notably, platelets are an abundant source of TGF-β, and platelets activated by tumor 
cells contribute further to microenvironment concentration of TGF-β (Olson, 2018).   Recent 
studies have explored the contribution of tumor-induced platelet activation and coagulation in 
pancreatic cancer progression (Maugeri, 2014). Platelets in contact with tumor cells induced 
metastasis by activating platelets to secrete CXCL5 and CXCL7 which are known neutrophil 
chemoattractants.  Activated platelets induce NET formation by stimulating neutrophils via cell 
mediated binding of von willebrand factor (vWF) to CD18 on neutrophils as well as soluble 
factors high mobility group box 1 (HMGB1) and platelet factors 4 (PF4)  (Fig. 7) (Cartesia, 
2016). NET histones elicit procoagulant activity providing a scaffold for thrombus formation and 
growth (Jurasz,2004). Providing answers to these cell interactions will require an improved 
understanding of the dynamic interaction between cancer cells and their stroma in designing new, 









Figure 7| Activated Platelet Neutrophil NETosis interaction. In humans (left), platelet activation induces thromboxane 
A2 (TXA2) formation. This activates release of high mobility group box 1 (HMGB1), platelet factor 4 (PF4), and von 
Willebrand factor (vWF). CD18 on neutrophils is bound to both vWF, bound to its platelet receptor, and glycoprotein 
(GP)lb. In mice (right), platelet induced NET formation is carried out through G-protein coupled receptors (GPCR) via 
HMGB1, PF4, as well as thromboxane 2 (TXA2) PF4 and RANTES. Additionally, binding between P-selectin 
expressed on platelets and PSGL-1 receptors on neutrophils, is also required for the release of NETs. Figure reproduced 
from (Carestia 2016)   
 
Potential Therapeutic Targets in Pancreatic Cancer 
In PDAC, clinical efforts to utilize immune therapy have been shown to be largely 
ineffective (Feng, 2017). While patients with other cancers benefit from increased survival rates 
with immunological check-point inhibitors enhancing anti-tumoral immune cell activity, only 
small subsets of PDAC patients respond to these treatments (Le, 2017). Thus, a major constraint 
is placed on immunotherapeutic strategies aimed to address PDAC. In comparison, infiltration of 
CD8+ tumor infiltrating leukocytes (TILs) into the tumor stroma has been identified as an 
important element in determining long-term survival in PDAC patients. Miksch et al., studied the 
importance of peritumoral tumor infiltrating leukocytes (CD3+, CD8+, CD20+ TILs, and 
CD66b+ tumor infiltrating neutrophils (TINs), to better understand these cell populations in 
relation to patient prognosis (Miksch, 2019). This group found that high infiltration of CD3+, 
CD8+, and CD20+ TILs was associated with improved overall and progression-free survival 




in order to combat the dense fibrotic PDAC tumor stroma and the immunosuppressive 
microenvironment which act to impede antitumoral immune response (Puleo, 2018).  
 
Multiple clinical trials have failed to demonstrate efficacy simply due to the aggressive 
nature of PDAC, with further impediments posed by the immunosuppressive tumor 
microenvironment (Manji, 2017). Furthermore, the dense stroma and rigid ECM architecture 
restricts effector immune cells from reaching their tumor sites in a phenomenon known as 
excluded infiltrate tumor microenvironment (Watt, 2013). Understanding the interconnected 
pathways and interactions between cells both systemically and within the stromal site will be 
crucial in designing clinical trials with improved clinical outcomes. Cancer cell interactions with 
the immune system is comprised of the following three phases: elimination, equilibrium, and 
escape phases (Mitall, 2014). First, the immune system recognizes and eliminates transformed 
cells. Transformed cells that escape the elimination phase then enter the equilibrium phase, in 
which the cancer cells undergo genomic editing and establish the tumor microenvironment that 
supports the growth of early neoplastic cells (Mitall, 2014). Finally, in the escape phase, cancer 
cells recruit immunosuppressive cells like MDSCs, tumor associated macrophages (TAMs) and 
regulatory T-cells, (Treg cells) (Wargo, 2016). In spite of such obstacles, studies have supported 
the viability of immunotherapeutic approaches to render cancer cells vulnerable by restoring the 
immune systems anti-tumor capability and response.  
 
Antibody-mediated immunotherapy involves targeting tumors to inhibit oncogenic 
signaling, immune suppression by using monoclonal antibodies (mAbs), antibody-drug 
conjugates, or radioimmunotherapy conjugates (Vonderheide, 2013). CD40 is a member of the 
tumor necrosis factor (TNF) receptor superfamily and is expressed primarily on antigen 
presenting cells (APCs) such as dendritic cells (DCs), macrophages, monocytes, B-cells and some 
non-immune cells like cancer cells (Amarsaikhan, 2017). The mechanism of anti-CD40 mAb is to 




suppression and induce T-cell independent but macrophage dependent tumor regression in 
pancreatic cancer patients (Torphy, 2018). One clinical trial with 22 patients who had advanced 
staged pancreatic cancer, showed increased B-cell surface expression of costimulatory molecules 
CD86, human leukocyte antigen complex (HLA-DR), and CD54 at 24-48 hours post-treatment 
when given weekly doses of gemcitabine in combination with anti-CD40 mAb, (Vonderheide, 
2013). In a clinical trial with 21 surgically incurable pancreatic cancer patients, three-week cycles 
of treatment with gemcitabine and a human agonist anti-CD40 mAb  showed increased overall 
survival of 7.4 months compared to those who received gemcitabine alone with average overall 
survival of 5.7 months (Bekaii-Saab, 2017).  
 
Combination therapies have gained traction by having shown some success in two or 
three drug combinations. The international phase III clinical trial (NAPOLI-1) study compared 
combination nanoliposomal irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) (5-
FU/nal-I) with leucovorin and infusional 5-FU alone and with nal-I alone after failure of 
gemcitabine-based therapy. The combination regimen was significantly better than 5-FU, 
prolonging mean overall survival from 4.2 to 6.1 months (Wang-Gillam, 2016). Consequently, 
the extent of trials employed to combat cancers illustrates the robust measures that tumors must 
escape in immune surveillance and progression. This would suggest that development of 
strategies to counteract and improve efficacy will require a combination of conventional 
treatment options, while reevaluating other potential therapeutic targets to improve patient 
survival. One such avenue involves studying the effect of neutrophil NETs on pancreatic cancer 
progression.  
 
Pancreatic cancer is an aggressive disease with a high mortality rate. The stromal 
microenvironment in this disease is composed of various cells that can promote tumor 




allows the cancer to evade immune detection and continue to grow. Highly influential in tumor 
progression and survival are neutrophils and their antimicrobial components that are comprised in 
NETs to normally fight disease, but when become tumor associated, can provide a survival 
advantage for cancer. Dysregulation of NET formation and the mechanisms behind its induction 
as well as neutrophil communication with other cancer associated cells within the 
microenvironment, provide avenues for novel strategies that combat disease. These include 
improving early detection strategies, bolstering antitumor immune responses, and development of 
combination therapies to target multiple components of disease initiators, while maintaining 
healthy immune function and patient tolerability to treatment in order to improve overall survival.  
Hypothesis 
Neutrophils impact pancreatic cancer proliferation and metastatic capability through NET 
















Chapter 2: Materials and Methods 
Cell Culture 
MiaPaca-2 (primary tumor) and Capan-1(liver metastasis) cells, obtained from Dr.Rakesh 
Singh’s lab group at the University of Nebraska Medical Center (UNMC). S2007 (lung 
metastasis) and S2013 (liver) were sublines cloned invitro from a human pancreatic cancer cell 
line (SUIT-2), along with AsPC1 (ascites fluid) were provided by the Hollingsworth group at 
UNMC. All cells were cultured as monolayers in T75 flasks. MiaPaca-2, AsPC1, and S2013 cell 
lines were grown in RPMI 1640 (Hyclone) medium supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 ug/ml) and streptomycin (100 ug/ml). Capan-1 cells were cultured in 
RPMI, 15% FBS, penicillin (100 ug/ml) and streptomycin (100 ug/ml) at 37oC in a humidified 
incubator with an atmosphere of 5% CO2.  
 
Preparation of Serum-Free Conditioned Medium 
 
Cells were cultured in T-75 flasks and grown to 75% confluence with 10ml of 
appropriate cell culture medium prior to application of serum-free RPMI medium. After 24 hours, 
serum free conditioned medium was collected in a 15ml conical tube and spun down at 2000 rpm 
for 5 minutes to separate any cells contained within the medium. Following centrifugation, 
supernatant was collected and conditioned medium (CM) stored in 15ml conical tubes at 4oC. 
Next, 20ul aliquots of conditioned medias were taken for colorimetric detection and quantitation 
of total protein using Pierce BCA Protein Assay Kit (Thermo Fischer Scientific). Accordingly, 
protein concentrations were determined and reported with reference to standards of a bovine 
serum albumin (BSA) for use in subsequent neutrophil NET Sytox Green experiments.  
 
Isolation and Purification of Mouse Bone Marrow Neutrophils 
Mice were euthanized in the University of Nebraska Medical Centers animal facility with 




removed from the distal part of the mice, including the skin covering the lower extremities. 
Muscles were detached from lower extremities using scissors and the acetabulum of the hip join 
was carefully dislocated to prevent breaking of the femur head.  Remaining muscles were 
removed from the 2 femurs and 2 tibias with scissors and the femurs and tibias were separated at 
the knee joint to prevent breaking of the bone ends. Bones were placed in 15ml conical tubes 
containing ice cold 10%PBS. The tube was transferred to a tissue culture hood for sterile 
technique to avoid neutrophil activation. A 1ml syringe was used to poke a hole at the bottom of 
four 0.5ml microcentrifuge tubes (Eppendorf) The bones were cut at the epiphyses and each 
placed inside of 0.5ml microcentrifuge tube to be transferred to 1.5ml microcentrifuge tubes 
(Eppendorf). The 0.5ml tubes were capped and both tubes transferred to be spun down in a 
microcentrifuge for 2-3 seconds allowing the bone marrow to flush out into the 1.5ml 
microcentrifuge tube. The 0.5ml tube containing bones was discarded and four 1.5 ml Eppendorf 
tubes were transferred back into the hood and bone marrow was gently resuspended with 1ml of 
Easy Sep buffer. Resuspended bone marrow was pipetted to a 50ml conical tube (Falcon) with a 
100um filter and a 10ul aliquot taken for initial cell counting using trypan blue exclusion. The 
50ml conical tube was centrifuged at 1,400 rpm for 10 min at 4 degrees Celsius.  The supernatant 
was discarded and resuspended with 1ml cold PBS. In a 15ml conical tube, 3ml of prepared 
Histopaque 1119 was added and subsequently overlaid with 3ml of Histopaque 1077 on top. 1ml 
PBS bone marrow cell suspension was slowly overlaid on top of Histopaque 1077 and the tube 
centrifuged for 30 min at 2,000rpm at 25 degrees Celsius with the brake disengaged. Neutrophils 
were collected at the interface of Histopaque 119 and Histopaque 1077 layers and transferred to 
15 ml round bottom polystyrene centrifuge tubes (Thermo Fisher Scientific). Collected 
neutrophils were washed 2x in 4ml Easy Sep buffer and centrifuged at 1,400 rpm for 7min at 4 
degrees Celsius. Neutrophils were then counted to determine viability. Typical yields of 




C57BL/6 mouse is approximately 6-12 million cells. For experiments utilizing human derived 
blood neutrophils, isolations were performed by Yangsheng Yu in Su lab group.  
Sytox NETosis Assay 
 
 For experimentation, 1ml aliquots of 1x106 neutrophils in RPMI were prepared for the 
following conditions: complete RPMI, complete RPMI +  Phorbol 12-myristate 13-acetate 
(PMA), MiaPaca-2 CM, Capan-1 CM, AsPC1 CM, S2013 CM. 200uL aliquots of 1ml 1x106 
were transferred to one well of a 96 well dark plate (triplicates) and incubated for 2-3 hours at 
37oC at 5% CO2. Following incubation, Sytox green (5uM) was added to neutrophil aliquots and 
allowed to incubate for 15 min in incubator. Fluorescence analysis was performed with plate 
reader at 488nm wavelength taken on EVOS FL Auto microscope. NET: Cell quantification was 
performed using Image J software.  
 
Cell Viability Assay 
 
Pure neutrophils were diluted in RPMI medium to the density of 1 × 106cells/mL/tube 
and spun down for 5 minutes at 1,400rpm in 3ml round bottom polystyrene tubes with 500ul 
(performed in duplicates). Neutrophils were then resuspended in RPMI medium, MiaPaca-2, 
Capan-1, AsPC1, and S2013 conditioned medias. Cell counts were taken using trypan blue 
exclusion assay at 0hrs, 18hrs, 24hrs, 36hrs. 
 
Coculture with Pancreas Cancer Cells 
 
 For coculture experiments, pancreatic cancer cells were each plated onto 24 well plates at 
concentrations of 4x104 for conditions of cancer cell, cancer cell+neutrophil, cancer 
cell+neutrophil+NET inhibitor (GSK 484, 10uM); each condition was done in triplicate. 24 hours 
following initial cancer cell plating, mouse bone marrow derived neutrophils were isolated and 




aliquots of neutrophils were pipetted onto neutrophil condition wells. 24 hours later all cancer 
cells were counted using trypan blue exclusion assay.  
 
Immunofluorescence of Rapid Autopsy Samples (RAP) 
 
 For immunofluorescent labelling of myeloperoxidase (MPO) and citrullinated H3 
(CitH3) by antibodies, RAP sectioned slides were first dewaxed and dehydrated by the following 
washing steps: xylene (10min, 2x), 100%EtOH (2min, 2x), 90%EtOH (2min), 80% EtOH (2min), 
70%EtOH (2min), 50% EtOH (2min), 1xTBST (15min), 1x TBS (5min). Following the 
dehydration steps, heat induced antigen retrieval was performed using a pressure cooker. Antigen 
retrieval with Tris-EDTA buffer (10mM Tris Base, 1mM EDTA solution, 0.05% Tween 20, pH 
9.0) was chosen for experiments. Prior to using the pressure cooker, 1L of Tris-EDTA buffer was 
microwaved to reduce the amount of time needed for samples to be in buffer prior to full pressure 
being reached. Slides were placed in white histology slide holders and filled with hot buffer to 
fully submerge sample sections. Remainder of buffer was poured in the pressure cooker 
surrounding the slide holders. Pressure cooker lid was secured and set cooker to “pressure” and 
selected “high” on settings for a total of 6 mutes. Once pressure was reached, slide holders were 
removed and allowed to cool on benchtop for 20 minutes. Once cooled, slide sections were 
circled with PAP pen and immersed in 1x TBS until ready for blocking solution. Sections were 
covered with blocking solution (10%serum in 1xTBS) and incubated for 1 hour. Following 
blocking, diluted primary antibodies ( 1%BSA in TBS) at concentrations of 1:50 (CitH3) and 
3.75ul in 500ul (MPO), were pipetted onto sections and allowed to incubate overnight in 
humidified chamber. The following day unbound primary antibodies were washed 3x in 1xTBST, 
10 mins each, with a final 10 min in 1xTBS. Secondary antibodies Alexaflour 488 donkey anti-
rabbit (CitH3) and 568 donkey anti-goat (MPO) (Abcam) were diluted 1:1000 in blocking 




antibodies were washed 3x in 1x TBS 10 minutes each. Slides were transferred to 70% EtOH 
(2min), and then distilled water until ready to mount with Prolong Gold and stored in dark at 4oC.  
MiaPaca In Vivo Experiment 
MiaPaca-luc cells were grown to confluency in complete RPMI media. Cells were 
trypsinized and washed three times with 1X PBS, and filtered using a 70uM filter. Cells were 
counted and reconstituted to give 300,000 cells per mouse for injection. Athymic Nude mice 
(NU/J) (Jackson Labs) were anesthetized with isoflurane, and pancreas was injected with 300,000 
cells. Mice were allowed to recover, and subsequent treatments began day 3 after injection. Mice 
were split into 2 groups of 5, and given isotype control antibody or 1A8 (Biolegend). Mice 
received a dose of 400ug on day 3 given intra-peritoneally, and subsequent doses remained at 200 
ug throughout the rest of the experiment. Mice were given D-luciferein ip twice a week and 
anesthetized and imaged using the IVIS Spectrum imager (Perkin-Elmer). Luciferase signal was 
quantified using the Living Image Software. Two days prior to termination of the experiment, 
mice were anesthetized, and ultrasound performed using the Vivo Imaging Sytem 3100. Analysis 
of data was performed using the Vevo Lab 3.1.1 software for quantification of 3D tumor volume, 




Cancer cells were observed through the EVOS FL Auto Microscope. Immunofluorescent 
images were captured with Apotome 2 camera via Zen Pro imaging software on Zeiss Axio 
Imager Z2 microscope. After images were captured, Adobe Photoshop was used for post image 












Statistical analysis was completed using Graphpad Prism 8 software. Data was analysed 
using a one-way ANOVA test to compare significant differences among each of the experimental 
conditions. T-tests were also used to compare conditions to the control. The data was considered 























Chapter 3: Results 
Effect of primary vs metastatic PDAC on neutrophil survival 
To better understand the impact of MiaPaca-2 (primary pancreatic line) with Capan-1 
(liver metastasis line) on neutrophil function, first a viability assay was performed in order to test 
if conditioned medias obtained from each cell line would impact neutrophil survival. 
Experimental conditions used were RPMI (control), in comparison with MiaPaca-2 and Capan-1 
conditioned medias. Neutrophil counts were obtained using trypan blue exclusion assay at time 
points of 0hr, 18 hr, 24 hr and 36 hrs. Percent fold changes in both Miapaca-2 and Capan-1 
showed a decrease in neutrophil cell number within the first 18 hours. Interestingly, at the 24 time 
point marked increases in both MiaPaca-2 and Capan-1 were seen to have neutrophils doubled. 
However, these changes were not statistically significant when compared to RPMI control. At the 
36 hr time point, >70% of neutrophils were not viable across all three conditions as illustrated in 
(Fig.8A). These initial results showing that conditioned medias from nonmetastatic cell lines did 
not show changes in neutrophil survival. Additional metastatic cell sublines S2013 (liver 
metastatic line) and S2007 (lung metastasis) derived from SUIT-2(liver metastasis), were used in 
subsequent experiments. These results illustrated in (Fig8.B). These findings show that pancreatic 
cancer media stimulates neutrophil proliferation although there were no significant differences 







































































Figure 8| Mouse bone marrow  and human peripheral blood derived neutrophil survival assay. (A) Serum free RPMI 
(control) was compared to MiaPaca-2 (primary tumor cell line) and Capan-1 (liver metastatic cell line) conditioned 
medias. (B) Serum free RPMI (control) was compared to Miapaca, Capan, S2013 (liver metastasis), and S2007 (lymph 









Primary vs Metastatic PDAC on neutrophil NET formation 
To evaluate the impact of primary versus metastatic PDAC on neutrophil NET formation, 
isolated mouse neutrophils were purified using density centrifugation and cultured in conditioned 
media from MiaPaca 2 (primary pancreatic line), Capan 1 (liver metastatic line), AsPC1 
(nonmetastatic ascites fluid) and S2013 (liver metastatic) cell line conditioned medias. To test the 
effect of nonmetastatic and metastatic cancer cells on neutrophil NET formation, neutrophils 
were incubated for 2-3 hours in pancreatic cancer cell conditioned medias. Serum free RPMI 
media with 2%BSA served as a negative control, while PMA served as a positive control. 
Extruded NETs were measured using a membrane impermeable dye (Sytox green) that is used to 
quantify extracellular DNA. Quantification via Styox green indicated varied results between 
triplicates of experiments. As seen in (Fig. 9A), there was no significance difference seen in 
between experimental conditions compared to RMPI control. Additional experiments utilizing 
human neutrophils were done to compare for potential differences in NET formation between 
mouse and human derived neutrophils in cancer conditioned media. These results illustrate that 
there were significant increases in NET induction by nonmetastatic vs metastatic conditioned 
medias (Fig. 9C,D). Particularly, Miapaca-2 conditioned media induced greater NETosis when 
compared to Capan-1. Concurrently, AsPC1 conditioned media induced greater NET formation 
than S2013. Based on these results, it was postulated that significant differences in NETosis 
between metastatic and nonmetastatic conditioned medias may have been resultant of an anti-
tumor response. Given this information, further experiments were conducted to investigate the 
neutrophil impact on pancreatic cancer growth via coculture of neutrophils with nonmetastatic 













































































Figure 9 A,B| Induction of NET formation by cancer cell conditioned medias. Neutrophils were isolated and cultured 
for 4 hours in RMPI+2%BSA, RPMI+2%BSA+PMA, Miapaca, Capan, AsPC1, and S2013 conditioned media all with 
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Figure 9 D,C| Induction of NET formation by cancer cell conditioned medias. Neutrophils were isolated and cultured 
for 4 hours in RMPI+2%BSA, RPMI+2%BSA+PMA, Miapaca, Capan, AsPC1, and S2013 conditioned media all with 
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NET Identification in Patient Rapid Autopsy Samples (RAP) 
To evaluate neutrophil infiltration and NET formation in clinical samples, primary and 
metastatic tumor samples were obtained from post-mortem pancreatic cancer patients who 
received a combination of chemotherapies, with one group being untreated. Samples were 
sectioned and stained with myeloperoxidase (MPO) as a measure of neutrophil infiltration and 
citrullinated H3 (CitH3) to quantify neutrophil NETs. In a sample group of six patients, three 
sites (pancreas, liver, lung) per patient were tested using immunofluorescence staining.  Figure 
10A illustrates quantification of neutrophil infiltration (MPO), NET formation (CitH3), and 
colocalization of neutrophils undergoing NETosis (MPO+CitH3) for each pancreatic and 
metastatic site. Across all three patients, colocalization counts were comparable in pancreas 
tumor and lung metastasis, and lowest in liver metastasis. Notably, no statistical significance was 
seen between the pancreas, liver, or lung groups. 
 
 
Figure 10A| Representative data illustrating neutrophil infiltration and NETosis colocalization between 6 patients 
matched samples of pancreas, liver, lungs. Sites of primary tumor and metastasis were patient matched and neutrophils 





































































Fig 10B| Representative immunofluorescence images of samples from untreated and chemotherapy treated pancreatic 
cancer patients with primary tumor, liver and lung metastasis. Cells were fixed, permeabilized and stained for 
myeloperoxidase (MPO, orange) citrullinated histone H3 (green), and DAPI (blue). NETs were identified by co-
localization of (MPO+CitH3).   
 
 Impact of Neutrophil NETs on PanCan growth in presence or absence of NET inhibitors 
Several recent studies have suggested neutrophil NETs can promote cancer cell 
proliferation. To understand how neutrophil NETs impact growth of metastatic vs nonmetastatic 
pancreatic cancer cells, mouse bone marrow neutrophils were isolated by density centrifugation 
and cultured in-vitro at a concentration of 10:1 (neutrophil: cancer) cell ratio. Other 
concentrations such as 5:1 and 1:10 were also tested but did not show significant differences in 
cancer cell killing. Following 24 hours of incubation, trypan blue exclusion assay was used to 
quantity change in cell growth. Nonmetastatic cell number was decreased by >40% when 
compared to metastatic cells (Capan-1, S2013), Decreases in cancer cell number were visualized 
prior to cell counting for gross comparison between conditions (Fig 11). The impact of cancer cell 
growth was abrogated by addition of GSK484, a PAD4 enzyme inhibitor necessary in NET 
formation.  
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Figure 11| Coculture of Mouse Neutrophils with Pancreatic Cell Lines. Comparison between primary pancreatic lines 
(MiaPaca, and AsPC1) and metastatic (S2013 and Capan) in direct coculture with mouse neutrophils.  Experimental 
conditions evaluated cancer cell only, cancer cell + neutrophil, cancer+neutrophil+GSK484 inhibitor, and 
cancer+GSK484 all ran in triplicate.  Percent reduction is the fold change in cell number due to neutrophil killing of 
cancer cells. Percent reduction with GSK484 is the change in inhibition of cell killing by prevention of histone 





• MiaPaca-2 – pancreatic 
(nonmetastatic) 
• AsPC1 – ascites fluid 
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• Capan1 – liver (metastatic) 
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 Effect of Neutrophil NETs on Cancer Growth In-Vivo 
Based on in-vitro coculture experiment results, subsequent studies looked to test whether 
neutrophil cell killing would have a similar impact on tumor cells in-vivo. First, Miapaca-2 cells 
were altered by viral infection to express luciferase (Miapaca-2 -luc), and luminescence measured 
to verify luciferase expression. A growth curve comparing MiaPaca-2 and MiaPaca-2(luc) cells 
was performed and trypan blue exclusion assay verified that no significant differences in cellular 
growth was apparent between the two cell lines due to luciferase expression (Fig 12).  MiaPaca-2-
luc cells were injected intraperitoneally into mice and two days prior to termination of the 
experiment, mice were anesthetized and ultrasound performed to measure change in tumor 
volume (Fig13 B,C).  It was observed that neutrophil depleted mice given administration of anti-
Ly6G antibody had higher bioluminescence readings compared to the isotype control (Fig 13A). 
This would suggest that depletion of neutrophils would inhibit cancer growth, contrary, to what 
was observed with in-vitro cocultures when comparing changes in tumor growth by inhibition of 
NET production. Tumor volume showed a statistically significant increase in neutrophil depleted 
mice, indicating that neutrophils do not play a role in reducing tumor burden and instead may 
































Figure 12. Growth curve comparing MiaPaca-2 with MiaPaca-2 luciferase expressing nonmetastatic cell lines. Cell 











Fig 13. In vivo data from mouse study for injection of the Miapaca-Luc cells. (A) Bioluminescence reading of Miapaca 
luciferase expressing cells. Over course of 33 days anti-Ly6G(1A8) neutrophil depleted mice showed increase in cancer 
growth. (B) Ultrasound quantification of tumor volume changes in isotype control versus increased change in 
neutrophil depleted anti-Ly6G mice. (C) Representative ultrasound imaging of isotype control and Ly6G neutrophil 
depleted mice groups.  
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Chapter 4: Discussion 
Through the preliminary experiments and those performed to validate initial findings, 
results were variable and at times contradict the original hypothesis of this study. Comparison of 
neutrophil survival in Miapaca-2 with Capan-1 conditioned medias on mouse derived neutrophils 
displayed higher number and viability at the 24hr time point. This could be indicative of a 
subpopulation of neutrophils present such as immature neutrophils after the 18hr time point. This 
is plausible as the isolation process for mice bone marrow derived neutrophils utilizing density 
centrifugation could have contained these immature cells. When compared to the human 
peripheral blood neutrophils a similar trend was observed with more neutrophils present at the 24 
hours across all conditions (Fig 8B), when comparing metastatic and nonmetastatic cell lines. 
However, the two cell lines S2013 and CaPan-1 had lower number of neutrophils than S2007 
(lung). This observation could indicate that as cancers progress further along the metastatic 
phenotype, they utilize neutrophils and their proteases by releasing soluble factors like 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and extend neutrophil survival 
time (Garnot, 2015). However, further exploration into the composition of chemokines and 
soluble factors released by each metastatic cell line and their interaction with neutrophils is 
needed to better understand differences in survival advantages provided by metastatic and 
nonmetastatic cell types.  
Mouse Sytox experiments comparing nonmetastatic (MiaPaca-2, AsPC1) and metastatic 
(Capan-1, S2013) conditioned medias on neutrophil NET formation showed differences with 
nonmetastatic conditioned medias having increased netosis. Although, these observations were 
not significant across cell line conditions. Conversely, when comparing the human blood derived 
neutrophils in these same conditions, significant differences were apparent in which 
nonmetastatic conditions induced NETosis in higher number of neutrophils as evidenced by 




species differences may be apparent when exposed to soluble factors produced by experimental 
conditioned medias. For example, neutrophils represent a smaller percentage of WBCs in mice 
(10-30%), whereas in humans, neutrophils are the predominant subpopulation of WBCs (Singhal, 
2017). This information when combined with species differences in immunological defense 
strategies in which mice display more immune tolerance mechanisms developed to maintain low 
host risk at the expense of higher pathogen number, whereas humans predominately have immune 
resistant response directed to deactivate and rapidly eliminate pathogens, could explain how 
neutrophils when exposed to similar experimental conditions, could display such dissimilar 
responses (Eruslanov, 2017).  
 The characterization and visualization of neutrophils in patient tumor tissues has been 
one of the few reliable detections methods that correlates neutrophil counts with patient 
prognosis.  With this understanding, our studies utilizing immunofluorescence antibodies for 
MPO and CitH3 showed no significant difference in NETs across pancreas, liver, and lung patient 
samples. However, a limitation of this study was low sample number of only six patients to 
examine. Concurrently, an additional limitation in this analysis is that neutrophil phenotypes and 
their activation states are difficult to quantify as their distribution and tumor heterogeneity can 
impact interpretation as to whether high neutrophil infiltration and netosis across samples were 
resultant of anti and pro-tumoral behavior. Moreover, though samples such as pancreas and lung 
display high accumulation of neutrophils and NETs, the different subset of neutrophils present in 
the tumor may be carrying different functions (Saha, 2016). Additionally, the absence or presence 
of chemotherapeutic drug regimens by each of the six patients could have altered cancer cell 
behavior and resultant cancer-neutrophil crosstalk as well as other cells within the 
microenvironment. For instance, significant changes in colocalization of MPO+CitH3 between 
chemotherapy treated versus non-treated groups was difficult to quantify as only one group of 




where greater number of both untreated and treated patient samples can be compared, could shed 
light on potential differences in neutrophil infiltration and activation in primary and metastatic 
tumor sites.  
 Cocultures of cancer cells with neutrophils in the absence and presence of GSK484 
inhibition supported initial results that indicated inhibition of netosis would rescue cancer cell 
killing. This was most apparent in the nonmetastatic (MiaPaca-2, AsPC1) than in metastatic cell 
lines (Capan-1, S2013). Since metastatic cell numbers were also reduced in neutrophil containing 
cocultures, it would appear as if neutrophils are exhibiting anti-metastatic behavior. In the case of 
tumor progression, however, these observations may also be indicative of a supportive function of 
neutrophils in metastasis (Coffelt, 2016). In circulation, neutrophil activation by metastatic cells, 
results in endothelial and epithelial tissue damage mediated by NE and MMP9 which facilitates 
infiltration and migration of cancer cells to establish metastatic niche at more distant sites. Thus, 
our observations in these studies must be understood in the context that neutrophil-cancer cell 
interactions are incomplete without considering the tumor microenvironment and additional cell 
populations that play an integral part in neutrophil-cancer behavior when over a longer time span.  
In relation to the impact of neutrophil NETs on cancer growth in-vivo, we found that 
depletion of neutrophils greatly attenuated the number of primary tumor cells in the peritoneal 
cavity, suggesting that neutrophils play an important role in primary tumor proliferation. This 
quantification was performed by measuring bioluminescence signals which provide insights as to 
the abundance and distribution of MiaPaca-2(luc) cells in mice. Notably, ultrasound images and 
tumor volume quantifications show significant increases in tumor size. However, when 
comparing this to the bioluminescence data (Fig 6A), it could be suggested that neutrophils may 
not be the only cell populations that aided in promoting tumor growth. In the first 15 days there 
was an initial lag in tumor size in the Ly6G depleted group when compared to control. However, 




group displayed minimal increases size. A potential explanation could be due to compensatory 
macrophage recruitment by cancer MiaPaca-2 (luc) cells. This has been observed in mouse tumor 
models targeting the inhibition of macrophages, with compensatory increases seen in tumor 
associated neutrophil infiltration at tumor sites (Nywening, 2018). For the control group, the 
initial increase in tumor size seen within the first two weeks could have elicited a slow antitumor 
macrophage response, but once macrophages remained in contact with the tumor cells over a 
period of 7 days, a transformation from antitumor to protumor phenotype may have occurred 
(Nywening, 2018). If this were the case, it could explain the subsequent increases in both the 
control and neutrophil depleted groups over the final 11 days of the study. This may be plausible 
as the Ly6G depleted groups’ higher rate of growth may have been mediated through tumor 
associated macrophages, myeloid derived suppressor cells, as no neutrophil would be present in 
order to induce a protumor response. Alternatively, neutrophils may have the opposite effect as 
that seen in the in-vitro experiments. Instead, neutrophils could promote cancer growth, but when 
depleted would result in the initial lag seen in the first 2-3 weeks of the study in the anti-Ly6G 
group. Supporting evidence for this is seen in studies which showed that neutrophil derived NE 
was localized to endosomes and potentiated inositolposphatidyl-3 kinase (IP3) pathway mediated 
lung cancer cell proliferation (Houghton, 2010).  
As it has been shown, neutrophils play a multifaceted role in cancer progression, 
proliferation, and metastasis. As illustrated in the experiments in this study, both anti-tumor and 
pro-tumoral roles have been postulated based on the data presented. Ultimately results of these 
studies highlight the possibility of tumor specific soluble factors mediating increases in neutrophil 
survival. In conjunction, neutrophil-cancer cell interactions and NETosis driven mechanisms 
affect neutrophil infiltration and NET formation in patient samples at primary and metastatic 
tissues sites. Notably, NET inhibition alleviates neutrophil antitumor responses in-vitro. 




proliferation by action of NETs and NET components such as NE and MMPs which are 
proinflammatory mediators pivotal in forming pro-tumorigenic environment which cancer cells 
utilize to grow, evolve, and metastasize to distant sites. Evident in this study is that mouse models 
allow for better understanding concepts of tumor biology, and microenvironment interactions. 
However, fundamental species differences in tumor heterogeneity and physiological interactions 
of neutrophil populations with cancer cells can impact their function as illustrated in the 
experiments discussed. These inherent differences pose challenges in translating data from mice 
studies to humans. Despite such hindrances, there is a continued need to develop and optimize 
novel approaches to studying this cell population in animal models and identify correlates to 
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